Table 4.

Comparison of anti-S protein antibody titers between users and non-users of glucocroticoids (GCs) within each treatment group and time point of sample extraction

	Pre-third dose		Post-third dose
	FC [95%CI]	p value	FC [95%CI]	p value
Overall	0.42 [0.22, 1.21]	0.0577	0.64 [0.22, 1.84]	0.4079
Non-biological	0.56 [0.17, 1.03]	0.3903	0.80 [0.19, 3.38]	0.7636
Biological	0.33 [0.10, 1.13]	0.0775	0.47 [0.12, 1.80]	0.2706
JAKi	0.38 [0.06, 2.56]	0.3180	0.54 [0.07, 3.91]	0.5418

Cells show Fold-changes (FC), 95% confidence intervals (CI) and p values of the corresponding comparison. FCs and p values were derived from a mixed-effects linear model where sex, age, rheumatic condition, treatment type, use of glucocorticoids, type of vaccine, sample type (pre- or post-third dose) and time from previous dose where included as fixed effects, as well as the interaction between: sex and sample type; treatment and sample type; rheumatic condition and sample type; use of glucocorticoids and sample type; time from second and third vaccine dose and sample type; glucocorticoids use and treatment regimen; and glucorticoids use and rheumatic condition. Individual effects were included as random effects in this model. SLE Systemic Lupus Erythematosus, RA Rheumatoid Arthritis, B27-AS HLA-B27 positive Ankylosing Spondylitis, PSA Psoriatic Arthritis, GCA Giant Cell Arteritis, GCs Glucocorticoids; JAKi JAK inhibitors, GCs Glucocorticoids, FC Fold-Change, 95%CI 95% confidence interval